Penumbra, Inc. (PEN) Company Overview

What does Penumbra do?

Penumbra, Inc. is a medical-technology company focused on devices used by specialist physicians to remove blood clots and treat neurovascular and peripheral vascular disease. Founded in 2004 and headquartered in Alameda, California, it designs, manufactures and sells catheter-based systems used in stroke thrombectomy, pulmonary embolism, acute limb ischemia, embolization, vascular access and selected neurosurgical procedures. The company trades on the New York Stock Exchange under PEN, although its standalone investment story is now shaped by the pending acquisition by Boston Scientific announced in January 2026.

Which clinical markets matter most?

Penumbra’s economic core is thrombectomy: removing clot quickly through minimally invasive aspiration systems. Its neuro thrombectomy portfolio addresses acute ischemic stroke, while its computer assisted vacuum thrombectomy platform treats peripheral arterial and venous clots, including pulmonary embolism. Embolization and access products support treatment of aneurysms, vascular malformations and other complex procedures.

Penumbra reports one operating segment, so investors must analyze product categories and geography rather than separate segment profit statements. The company’s official company overview emphasizes a global model built around engineering, manufacturing, clinical evidence and physician education rather than recurring software or service revenue.

How does Penumbra make money?

Penumbra earns revenue primarily when hospitals and healthcare providers purchase disposable catheters, separators, aspiration tubing, coils and related procedure products, together with supporting capital equipment such as aspiration pumps. The installed clinical workflow matters because a hospital that trains physicians and staff on a platform can continue buying compatible single-use products. This creates repeat procedure revenue without making the business a formal subscription model.

Which product category generates the most revenue?

In the quarter ended March 31, 2026, thrombectomy revenue was $253.9 million versus $226.5 million a year earlier, growth of roughly 12.1%. Embolization and access revenue was $120.8 million versus $97.6 million, growth of about 23.8%. The smaller category therefore grew faster, which matters because it broadens the revenue base and reduces dependence on a single clinical use case.

How do geography and distribution affect margins?

The United States remains the main market because Penumbra has a direct commercial organization, established reimbursement pathways and high procedure volumes. International revenue adds diversification but also introduces distributor economics, foreign-exchange exposure and varied regulatory timing. In FY2025, U.S. revenue was $1.092 billion, or 77.8% of total revenue, while international revenue was $311.9 million, or 22.2%.

What does Penumbra’s latest quarter show?

The Form 10-Q for the quarter ended March 31, 2026 shows continued double-digit revenue growth, strong operating cash generation and a lower reported net profit than the prior-year quarter. The quality of the quarter is therefore mixed: commercial momentum remained healthy, but transaction costs and operating expenses constrained earnings.

Why did cash flow look stronger than net income?

Operating cash flow of $87.0 million exceeded net income by $54.4 million in Q1 2026. Non-cash items contributed $18.9 million, while working-capital changes contributed $35.5 million. Accounts receivable declined, accrued expenses increased and accounts payable rose, partly offset by a $9.0 million inventory build. A simple free-cash-flow approximation—operating cash flow minus capital expenditures—produces roughly $73.3 million for the quarter.

What does the annual baseline add?

FY2025 revenue rose 17.5% to $1.404 billion, operating income reached $189.2 million and net income was $177.7 million. The annual figures benefited from lapping the 2024 exit of the immersive healthcare business, which had generated $115.3 million of impairment and related charges. Researchers should therefore separate genuine operating progress from the easier comparison created by the disappearance of those charges.

Which turning points built Penumbra’s current position?

Penumbra’s history is best understood as a sequence of adjacent clinical-market expansions. Each step added another catheter platform, physician relationship or manufacturing capability while keeping the company centered on minimally invasive treatment.

1. 2004
   Company founded, creating the engineering and physician-development culture that still anchors product design.
2. 2007
   Commercial entry into thrombectomy established the core franchise in clot removal.
3. 2008
   Expansion into access devices broadened the procedure toolkit and hospital account relevance.
4. 2011
   Entry into embolization added coils and complementary products for aneurysm and vascular-malformation treatment.
5. 2014
   Peripheral thrombectomy and neurosurgical expansion widened the addressable market beyond stroke.
6. 2024
   Exit from immersive healthcare removed a non-core business and caused $115.3M of impairment and related charges.
7. 2026
   Agreement to be acquired by Boston Scientific reframed the story around strategic integration and transaction completion.

Why was the immersive-healthcare exit important?

The decision to wind down immersive healthcare clarified that management would concentrate capital and talent on interventional medical devices. It also exposed the danger of moving too far from the company’s core competencies: the 2024 exit produced a $76.9 million impairment charge, a $33.4 million inventory charge and $5.0 million of severance and related costs. By FY2025, those charges were absent, improving comparability and reported profitability.

What gives Penumbra a competitive advantage?

Penumbra’s moat is not a single patent or brand claim. It is a system of clinical evidence, product iteration, specialized sales coverage, manufacturing know-how and physician familiarity. In clot-removal procedures, performance, ease of use, deliverability and response time matter directly to patient outcomes, so switching decisions are more complex than comparing unit prices.

How do product breadth and workflow familiarity reinforce each other?

Which competitors pressure the business?

The company faces major diversified medical-device groups and focused neurovascular specialists. Competitive pressure is strongest where rivals can bundle products across hospital departments, fund large clinical programs or use established sales channels. Penumbra counters with speed of development, focused expertise and a broad aspiration-thrombectomy portfolio. However, the pending Boston Scientific transaction itself signals that scale, distribution and product bundling are increasingly important in the market.

How financially strong is Penumbra?

The balance sheet was strong before the proposed acquisition. At March 31, 2026, cash and cash equivalents were $241.3 million and marketable investments were $374.4 million, for combined liquidity of about $615.7 million. Current assets totaled $1.275 billion, while working capital had been $1.034 billion at December 31, 2025. This liquidity supports inventory, manufacturing expansion, clinical programs and product launches.

What drives gross margin?

Medical-device gross margin depends on product mix, manufacturing yields, labor and material costs, pricing and scale. FY2025 gross profit was $942.4 million on revenue of $1.404 billion. R&D spending was $89.8 million, or 6.4% of revenue, compared with $94.8 million and 7.9% in FY2024. Lower R&D intensity improved current earnings, but sustained innovation remains essential because product cycles and clinical evidence drive future adoption.

How capital intensive is growth?

Capital expenditures were $63.7 million in FY2025, including payments related to a Costa Rica manufacturing project expected to cost about $58 million. Inventories reached $431.5 million at year-end 2025 and $438.5 million at March 31, 2026. Inventory supports service levels and growth, but it also creates write-down risk when products change or demand forecasts prove too optimistic.

Who owns Penumbra stock, and why does governance matter?

Penumbra has one class of common stock with one vote per share, so it is not a dual-class controlled company. The 2025 proxy reported 38,683,650 shares outstanding as of March 31, 2025. Governance was moving toward greater stockholder alignment through proposals to declassify the board and eliminate supermajority voting requirements.

How does the Boston Scientific deal change the investor profile?

Under the January 2026 merger agreement, each Penumbra share was valued at $374, with holders able to elect cash or 3.8721 Boston Scientific shares, subject to proration. Aggregate consideration is expected to be approximately 73% cash and 27% Boston Scientific stock. Founder and chief executive Adam Elsesser indicated that he would elect Boston Scientific shares for all of his Penumbra holdings, signaling continued exposure to the combined company.

That structure changes the analytical question. Standalone ownership and long-term capital allocation matter less than transaction completion, regulatory approvals, proration mechanics and the future economics of Boston Scientific shares received by electing holders. The relevant official governance foundation remains Penumbra’s 2025 definitive proxy statement and the transaction filings.

Which KPIs best explain Penumbra’s performance?

Revenue growth alone is not enough. Penumbra’s model depends on procedure adoption, product mix, gross margin, inventory discipline and cash conversion. These measures reveal whether innovation is translating into durable economics.

What should researchers monitor each quarter?

What opportunities and risks could change Penumbra’s outlook?

The most important opportunity is continued expansion of mechanical thrombectomy across stroke, pulmonary embolism and peripheral vascular disease. Better devices, faster workflows and stronger clinical evidence can increase the number of eligible patients and the share treated with aspiration-based systems. The company can also use its access and embolization portfolio to deepen hospital relationships.

Which operating risks are most material?

The Q1 2026 earnings filing explicitly identifies competition, product-introduction delays, manufacturing difficulties, clinical-trial outcomes, pricing pressure, regulatory actions and transaction uncertainty as risks. The 2025 Form 10-K provides the fuller risk-factor framework.

Why is the pending acquisition the central near-term risk?

The merger is expected to close in 2026, subject to stockholder approval and customary conditions. Failure or delay could create employee departures, management distraction and uncertainty among customers. Completion would shift the risk toward integration: preserving Penumbra’s innovation culture while using Boston Scientific’s scale, channel reach and balance sheet.

Why does Penumbra matter for valuation?

Before the merger agreement, a standalone valuation would have depended on revenue growth, gross-margin durability, R&D productivity, working-capital needs and terminal market penetration. Thrombectomy growth would be the main top-line driver, while embolization and access growth would influence diversification and mix. Gross margin and sales-force leverage would determine whether double-digit revenue growth translated into faster operating-profit growth.

Which variables belong in a DCF?

The transaction changes that framework. The relevant comparison is now between the value offered under the merger terms and the probability-weighted value of completion, delay or failure. Because the consideration includes both cash and Boston Scientific shares, the economics also depend on proration and the market value of the stock component. This is merger-arbitrage analysis rather than a conventional long-duration standalone DCF.

What is the key takeaway from Penumbra analysis?

Penumbra built an important medical-device franchise by applying focused engineering and physician collaboration to difficult clot-removal procedures. The business combines repeat disposable-product sales, high gross margins, strong cash generation and a growing set of adjacent neurovascular and peripheral vascular products. FY2025 revenue of $1.404 billion, a 67.1% gross margin and $238.7 million of operating cash flow show that the platform had reached meaningful scale.

The strongest part of the story is the thrombectomy engine: Q1 2026 thrombectomy revenue was $253.9 million, while faster-growing embolization and access revenue reached $120.8 million. The main strategic tension is that growth requires continued product innovation, inventory, manufacturing capacity and specialized commercial support. Those same investments create execution risk if clinical uptake, product quality or demand forecasts disappoint.